Sick Economics

Searching For Healthy Profits In The Stock Market

Biotech Investing

Biotech Investing

Biotech investing means betting on scientific innovation. Let’s talk about how you can turn innovation into profit.

 

12 min read

TOP 3 CRISPR GENE EDITING STOCKS

3 years ago

By Aidan Asbill, Biotech Analyst    Intellia Therapeutics ($NTLA) shocked the gene-editing field with the announcement of data from the...

promising neuroscience companies
7 min read

3 PROMISING NEUROSCIENCE COMPANIES

3 years ago

By Owen Marino, Biotech Analyst   Arguably the hottest topic in biotech this past month has been the approval of...

undervalued biopharmaceutical stocks
10 min read

3 UNDERVALUED BIOPHARMA STOCKS

3 years ago

By John Kehoe, Equity Analyst   Valuation within the biotech industry can be extremely difficult. Many biotech and pharmaceutical companies...

Illumina Stock ILMN Worth The Risk
7 min read

IS ILLUMINA WORTH THE RISK?

3 years ago

By John Kehoe, Equity Analyst    When searching for potentially rewarding investments within the biotech industry, it is helpful to...

orphan drug stocks
10 min read

THE ORPHANS IN YOUR PORTFOLIO

3 years ago

John Kehoe, Biotech Analyst   The development of drugs and medicine can be a long and an expensive process for...

sage therapeutics stock performance
10 min read

IS THIS THE END FOR SAGE THERAPEUTICS?

3 years ago 1

By Aidan Asbill, Biotech Analyst   Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies to treat central...

3 controversial drugs stocks
7 min read

3 CONTROVERSIAL DRUGS

3 years ago

By Dabin Im, Pharmaceutical Analyst  Questionable Road to Approval  The FDA’s recent approval of Biogen’s drug, aducanumab, for Alzheimer’s disease...

diabetes stocks 2021
8 min read

3 PROMISING DIABETES STOCKS

3 years ago 4

By Dabin Im, Biotech Analyst Here is a little crash course on one of the most common health conditions in...

Subscribe To The Rx Newsletter

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT